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The Stratis disposable syringe jet injection (DSJI) system (PharmaJet Inc., Denver, USA) delivers vaccine
utilizing a spring powered energy source to create a ﬁne high-velocity jet of liquid that directly
penetrates the skin without using a needle. We performed a study to collect data on the effect of the
Stratis DSJI device on inﬂuenza immunization in 46 predominantly elderly subjects (28M, 18F; mean
age 61 years) who were randomized 1:1 to receive Fluvax 2012 trivalent inactivated inﬂuenza vaccine
via preﬁlled N–S or Stratis DSJI. H1N1 seroprotection was not signiﬁcantly different for vaccine delivered
by DSJI (86.4%, 95% CI 72.1–100) or N–S (79.2%, 95% CI 63.0–95.4), and likewise for H3N2 and B strains.
The DSJI had a 2-fold higher mean injection pain score (DSJI: 3.0 versus N–S 1.58, p = 0.045) plus
increased rates of swelling and tenderness but this was offset by a lower rate of elicited systemic reac-
tions, particularly the frequency of post-immunization headaches (DSJI: 9% vs N–S: 33.3%). This study
suggests that subject to conﬁrmation of non-inferiority in an appropriately powered study, the Stratis
DSJI is a viable alternative strategy for the administration of seasonal inﬂuenza vaccines with particular
appeal for individuals with needle phobia. Australia New Zealand Clinical Trials Register:
ACTRN12612000709842.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 1. Introduction
Inﬂuenza is a highly contagious and potentially deadly viral
disease, particularly in the elderly, those with chronic disease
and young children. Seasonal trivalent inactivated inﬂuenza virus
(TIV) vaccines are used to boost neutralizing antibody titers and
thereby help prevent severe disease. TIV vaccines are most
commonly administered either by intramuscular or deep subcuta-
neous injection using a needle and syringe (N–S) method. Although
this is a reliable and well-tested method, downsides include the
risk of needle stick injuries to the operator [1] and avoidance ofimmunization by subjects suffering from needle phobia [2].
Alternative approaches for TIV vaccine administration include
aerosol delivery or mucosal application [3,4], intradermal injection
[5], and transdermal patch [6]. In particular, recent advances in
intradermal delivery devices, e.g. the Soluvia™ id-needle system
(Becton-Dickenson, USA) has enabled intradermal inﬂuenza vac-
cines to be developed for the ﬁrst time as commercial products,
e.g. Intanza (Sanoﬁ Pasteur, Lyon, France). Another major advance
in vaccine delivery has been in the area of jet injector devices [7]
including the recently-developed Stratis disposable syringe jet
injection (DSJI) device. The Stratis DSJI delivers vaccine using a
hand-held, spring-powered, energy source to create an extremely
ﬁne high-velocity jet of liquid that directly penetrates through
the skin without the need for a needle. The Stratis DSJI is approved
as a medical device for human use by the US Food and Drug
Administration (FDA) and employs a single-use, sterile, auto-dis-
able needle-free syringe for vaccine delivery. The delivery of TIV
vaccine through this needle-free device could offer a superior
experience compared to N–S injection, particularly for needle
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stick injury risk.
Vaccine labeling is clear on the route of parenteral administra-
tion (IM, SC, ID), but is most often silent on the method of
administration. While N–S is most commonly used, DSJI devices
have been used for over 50 years across a wide range of vaccines
[7–10]. However, on October 26th, 2011 the US FDA issued a com-
munication to ‘‘inform the public that inactivated inﬂuenza vac-
cines labeled for IM injection are intended for administration
using a sterile needle and syringe.’’ This recommendation was
based, in part, on the fact that safety and effectiveness information
submitted to the FDA by vaccine manufacturers in support of the
inﬂuenza vaccine approvals were acquired with N–S, and not DSJI.
This delivery method-speciﬁc approach to vaccine approval signals
a signiﬁcant departure on the part of the FDA from previous
practice.
The primary aim of this pilot clinical study was to test the utility
of the Stratis DSJI for delivery of TIV vaccine as compared to a pre-
loaded N–S with the aim of collecting data to inform the design of a
larger, appropriately powered, immunogenicity non-inferiority
study. A secondary aim was to collect preliminary data on the fre-
quency and severity of local and systemic side effects between the
two administration approaches and to assess subject satisfaction
with the Stratis DSJI device.2. Methods
2.1. Study site
The study was conducted as a single site study sponsored by
Vaxine Pty Ltd. and performed within the Australian Respiratory
and Sleep Medicine Institute at Flinders Medical Centre (FMC),
Adelaide, Australia with recruitment undertaken between March
30, and August 24, 2012. The study was approved by the Flinders
Clinical Research Ethics Committee. The study was registered on
the publicly accessible Australia New Zealand Clinical Trials Regis-
ter (http://www.anzctr.org.au) under the trial record number
ACTRN12612000709842.
2.2. Study subjects
After obtaining informed consent adult volunteers were ran-
domized to receive their TIV vaccine through either the Stratis DSJI
or a preloaded N–S on a 1 to 1 basis. Randomization was performed
by use of blinded envelopes containing randomization codes pre-
pared independently using the randomization program available
at http://www.radomization.com. The study population included
ambulatory subjects and did not exclude those of older age or with
chronic disease. Inclusion criteria included males or females
18 years or older, able to provide written informed consent and
willing to comply with the protocol for the study duration. Exclu-
sion criteria included history of vaccination with 2012 seasonal
inﬂuenza vaccine or of serious vaccine or egg allergy, women of
childbearing potential unless using a reliable and appropriate con-
traceptive method, pregnant or lactating women, receipt of an-
other investigational agent within 14 days preceding initiation of
treatment or any other serious medical, social or mental condition
which, in the opinion of the investigator, would be detrimental to
the subjects or the study.
2.3. Study vaccine and devices
Fluvax 2012 (CSL Ltd., Parkville, Australia) was purchased as a
single dose preloaded plastic syringe with staked needle contain-
ing 15 ug hemagglutinin (HA) dose of each of A/California/7/2009(H1N1pdm09), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
in a volume of 0.5 ml. In the control needle and syringe (N–S)
group the vaccine was administered as supplied by the manufac-
turer in a preﬁlled syringe with 1/20 needle for deep subcutane-
ous/intramuscular injection into the deltoid muscle. For the
Stratis DSJI group, immediately prior to use 2 vials of Fluvax
2012 vaccine were dispensed into a sterile 2 ml vial and then using
the ﬁlling adaptor supplied by PharmaJet, 0.5 ml of the vial con-
tents were aspirated into the DSJI syringe which was then loaded
onto the Stratis DSJI device prior to injection into the deltoid mus-
cle. Due to the very different nature of the delivery devices, neither
subjects nor clinical staff were blinded to the study arm to which
subjects were randomized.
2.4. Study visits
After assessment for eligibility criteria and providing informed
consent, study subjects had a baseline clinical assessment, includ-
ing medical history. Blood samples were drawn for measurement
of baseline titers of anti-inﬂuenza antibodies. Each eligible subject
was then randomized to receive vaccination in one of the study
groups. Immediately following immunization subjects recorded
their pain score using a visual analogue chart. Subjects were ob-
served for 30 min following immunization and then rescored their
pain with the same visual analogue chart. Those subjects who re-
ceived their vaccine via the Stratis DSJI were asked to complete a
copy of a questionnaire to assess their perceptions of the injection.
Subjects were then provided with a diary to take home with them
to record any symptoms or adverse events. Day 1 post-immuniza-
tion subjects were telephoned to check their condition and to en-
quire about any adverse reactions. They then returned on day 28
post-immunization for collection of the subject diary, recording
of any additional adverse events, and to provide a ﬁnal blood sam-
ple for immunogenicity studies. Adverse events were graded using
the ‘‘FDA/CBER toxicity grading scale for healthy adult and adoles-
cent volunteers enrolled in preventative vaccine clinical trials’’
(www.fda.gov/cber/gdlns/toxvac.htm). Those subjects who re-
ceived their vaccine via the Stratis DSJI were also asked at this ﬁnal
visit to complete a second copy of the questionnaire they had com-
pleted previously. The CONSORT Flow Diagram for the study is
shown in Fig. 1.
2.5. Inﬂuenza assays
Red blood cell hemagglutination inhibition assays were per-
formed in the Dept. of Endocrinology, Flinders Medical Centre
using previously described techniques [11]. They were performed
against each of the vaccine strains, namely A/California/7/2009
(H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008 on ser-
um samples of all subjects taken prior to immunization and at
28 days post-immunization.
2.6. Statistical evaluation
The analysis included listings of objective response according to
currently pertaining WHO inﬂuenza vaccine criteria using the
hemagglutination inhibition (HI) assay, including seroconver-
sion = 4-fold increase in titer over baseline, seroprotection = post-
immunization titer of 1:40 or greater and potency = Geometric
Mean of Titer (GMT) Ratio. Exact binomial conﬁdence intervals
were reported for all proportional end points. Reported p-values
are two-sided, with no adjustment for multiple testing; p 6 0.05
was considered signiﬁcant. GMT and 95% conﬁdence intervals
were computed by taking the exponent of the mean and of the
lower and upper limits of the 95% conﬁdence intervals of the loge-
transformed titers. Differences in mean values were compared
Fig. 1. CONSORT 2010 Flow Diagram –2012 Inﬂuenza Vaccine DSJI Study.
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using the GraphPad online calculator. As this was a pilot study, no
formal sample size estimation was performed. A minimum sample
size of 20 subjects per group was chosen in order to provide
adequate evaluation of the study endpoints and allow estimates
of treatment effect to be generated to guide power calculations
for design of a future larger non-inferiority study.Table 2
Vaccine efﬁcacy.
N–S (95% CI) DSJI (95% CI)
A/California/7/2009 (H1N1)3. Results
3.1. Demographics
Twenty-four subjects received Fluvax by staked needle and
syringe (N–S group) and 22 subjects received the same Fluvax vac-
cine via the Stratis DSJI (DSJI group). Overall, the two groups were
well matched, although there was a slightly higher mean age and
ratio of male to female subjects in the DSJI group (Table 1). This
was an older population with mean age over 60 years, and the
majority of subjects (>90%) were taking one or more medicationsTable 1
Subject demographics.
N–S DSJI
Number of subjects 24 22
Male: n (%) 13/24 (54%) 15/22 (68%)
Female: n (%) 11/24 (46%) 7/22 (32%)
Age: mean (SD) 59.5 (16.1) 62.5 (9.8)
Age: 18–59 years: n (%) 6 (25%) 7 (31.8%)
Age: 60–78 years: n (%) 18 (75%) 15 (68.2%)
Caucasian (%) 24/24 (100%) 22/22 (100%)
Previous ﬂu vaccine n (%) 23/24 (96%) 22/22 (100%)
On chronic medication n (%) 22/24 (92%) 20/22 (91%)for chronic medical conditions. All subjects completed the study
protocol with no withdrawals due to post-immunization adverse
events and no subjects being lost to follow up.3.2. Vaccine immunogenicity
Vaccine efﬁcacy as measured by hemagglutination inhibition
(HI) responses to immunization was modest (Table 2), which likely
reﬂected the elderly demographics of the study population, with
such subjects known to have reduced TIV vaccine responses [12].
For the H1N1 vaccine strain, the proportion of subjects achieving
a seroprotective titer was not signiﬁcantly different between the
DSJI group (86.4%, 95% CI 72.1–100%) and the N–S group (79.2%,GMT (pre/post) 29.1/75.5 34.2/80.0
Seroconversion 33.3% (14.4–52.2) 31.8% (12.3–51.3)
Seroprotection 79.2% (63.0–95.4) 86.4% (72.1–100)
GMT fold increase 2.6 (1.4–3.8) 2.3 (1.3–3.4)
A/Perth/16/2009 (H3N2)
GMT (pre/post) 23.8/42.4 23.4/49.9
Seroconversion 12.5% (0.7–25.7) 31.8% (12.3–51.3)
Seroprotection 66.7% (47.8–85.6) 72.7% (54.1–91.3)
GMT fold increase 1.8 (1.0–2.6) 2.1 (1.1–3.2)
B/Brisbane/60/2008
GMT (pre/post) 11.2/16.8 15.5/22.0
Seroconversion 4.1% (3.8–12.0) 4.5% (4.2–13.2)
Seroprotection 16.7% (1.8–31.6) 18.2% (2.1–34.3)
GMT fold increase 1.5 (0.9–2.1) 1.4 (0.7–2.2)
100
(%
) N-S
42 N. Petrovsky et al. / Trials in Vaccinology 2 (2013) 39–4495% CI 63.0–95.4%, n.s.). A similar result was obtained for the H3N2
and B vaccine strains (Table 2).Pa
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Fig. 3. Local adverse events for inﬂuenza vaccine administered by Stratis DSJI or
needle and syringe (N–S). Subjects were asked to record any symptoms or adverse
events in a diary they took home with them and then returned on day 28 post-
immunization.3.3. Vaccine tolerability
Post-immunization pain scores were assessed by visual
analogue pain charts completed by study subjects immediately fol-
lowing and then 30 min post-immunization. Overall, both injection
methods were well tolerated (Fig. 2). The DSJI was associated with
a signiﬁcantly higher mean pain score at the time of injection
(mean pain score – DSJI 3.0 versus N–S 1.58, p = 0.045 by Student
t-test) with several subjects in the DSJI group reporting pain scores
of 8 or more out of 10. Overall, the proportion of subjects recording
pain scores of 3 or higher at the time of immunization was higher
for the DSJI group (10/22, 45.4%; 95% CI 24.6–66.2%) than the N–S
group (4/24, 16.6%; 95% CI 1.7–31.5%, p = 0.05 by Fisher’s exact
test). However, in all cases injection site pain abated rapidly and
there was no signiﬁcant difference between groups in injection site
pain scores 30 min post-immunization, with no pain score in the
DSJI group greater than 3 out of 10 by this time.3.4. Local adverse reactions
Local injection site reactions were ascertained by a telephone
call to all subjects the day following their immunization, and by
records from subject diaries returned on post-immunization day
28. Subjects were asked to record in their diary the occurrence of
any local reactions (pain, tenderness, redness, swelling and bruis-
ing) and also asked to record its duration and severity (Fig. 3).
There were a higher total number of local adverse reactions in
the DSJI group (total 43 AE amongst 22 subjects) than in the N–S
group (total 19 AE amongst 24 subjects). In particular, there were
signiﬁcant differences in rates of tenderness (DSJI: 17/22, 77%; 95%
CI 59.41–94.59% versus N–S: 10/24, 41.7%; 95% CI 21.97–61.43%;
p = 0.02 Fisher’s exact test) and swelling (DSJI: 10/22, 45.5%; 95%
CI 24.7–66.3% versus N–S: 1/24, 4.2%; 95% CI 3.83–12.23%,
p < 0.001) with a non-signiﬁcant trend towards higher rates of
bruising and redness in the DSJI group. However, all of the local
reactions in the DSJI group were graded as mild only (Grade 1) with
just one case of Grade 2 tenderness occurring in the N–S group.
Most local reactions abated within 4 days with the majority lasting
less than 2 days.0 1 2 3 4 5 6 7 8 9 10
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Fig. 2. Post-immunization pain scores of inﬂuenza vaccine administered by Stratis
DSJI or needle and syringe (N–S). Post-immunization pain scores assessed by visual
analogue pain charts recording pain on a scale of 0 (no pain) to 10 (worst
imaginable pain) completed by study subjects immediately following inﬂuenza
immunization.3.5. Systemic adverse reactions
Systemic adverse reactions were ascertained by a telephone call
to all subjects the day following their immunization, and by re-
cords from subject diaries returned on day 28. Subjects were asked
to record in their diary the occurrence of any systemic reactions
(fever/chills, headache, muscle ache, fatigue, nausea, diarrhea)
and to record its duration and severity. By comparison to local
reactions, which were higher in the DSJI group, there was a signif-
icantly lower rate of elicited systemic reactions (fever, headache,
muscle ache, fatigue, nausea, diarrhea) in the DSJI compared to
the N–S group. Signiﬁcantly fewer subjects (p = 0.02) in the DSJI
group (2/22, 9.1%; 95% CI 2.92–21.12%) experienced one or more
systemic reactions as compared to the N–S group (10/24, 41.7%;
95% CI 21.97–61.43%). Interestingly, there was a strong trend that
did not quite reach statistical signiﬁcance (p = 0.07) to a reduced
rate of headaches (Grade 1 or 2) post-immunization in the DSJI
group (2/22, 9.1%, 95% CI 2.92–21.12%) compared to the N–S
group (8/24, 33.3%, 95% CI 14.44–52.16%).
3.6. Subject perceptions of the stratis DSJI device
A simple questionnaire was administered to all subjects who re-
ceived immunization via the DSJI, both immediately after immuni-
zation and again on the Final Study Visit on day 28 (Table 3). A high
frequency of subjects in the DSJI group (77.3%) reported no anxiety
or fear about needles. Immediately after immunization 86.4% of
subjects reported being moderately to extremely satisﬁed with
having the inﬂuenza vaccine through the DSJI and 81.8% still felt
this way 4 weeks later. Subject acceptability of the DSJI was high,
with over 81.9% expressing a moderate to extreme interest in hav-
ing their next vaccine using the DSJI. Two subjects (9.1%) reported
immediately post-immunization being not at all satisﬁed with the
DSJI which correlated with very high injection pain scores reported
by the same subjects (data not shown).4. Discussion
The study within the limitations of its size and power demon-
strated that administration of TIV vaccine via the Stratis DSJI had
no adverse effect on TIV immunogenicity when compared to
administration via the pre-ﬁlled N–S. This is consistent with the
ﬁndings of a recent comprehensive review byWeniger and Papania
of alternative vaccine delivery methods that concluded the
Table 3
Stratis DSJI consumer questionnaire.
Questions Answers Day 0 (n = 22) Day 28 (n = 22)
Q1. Do you have anxiety or a fear of needles? Not at all 17 (77.3%) 21 (95%)
Mildly 3 (13.6%) 1 (4.5%)
Somewhat 1 (4.5%) 0
Moderately 1 (4.5%) 0
Extremely 0 0
Q2. Overall, how painful or physically uncomfortable was your needleless injection? Not at all 8 (36.4%) 10 (45.5%)
Mildly 7 (31.8%) 7 (31.8%)
Somewhat 3 (13.6%) 1 (4.5%)
Moderately 3 (13.6%) 2 (9.1%)
Extremely 1 (4.5%) 2 (9.1%)
Q3. How satisﬁed were you with having your ﬂu vaccine via a needleless injection? Not at all 2 (9.10%) 0
Mildly 0 1 (4.5%)
Somewhat 1 (4.5%) 3 (13.6%)
Moderately 6 (27.3%) 5 (22.7%)
Extremely 13 (59.1%) 13 (59.1%)
Q4. If it were available, would you want to have your next vaccine via a needleless injection? Not at all 2 (9.1%) 2 (9.1%)
Mildly 0 4 (18.2%)
Somewhat 2 (9.1%) 0
Moderately 8 (36.4%) 2 (9.1%)
Extremely 10 (45.5%) 14 (63.6%)
Q5. How likely are you to recommend needleless injections to a friend or family member? Not at all 3 (13.6%) 1 (4.5%)
Mildly 0 4 (18.2%)
Somewhat 2 (9.1%) 2 (9.1%)
Moderately 9 (40.9%) 4 (18.2%)
Extremely 8 (36.4%) 11 (50%)
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than, vaccine administered by N–S [13]. Notably, no studies of TIV
vaccine administered via DSJI devices have found a reduction in
vaccine immunogenicity [14,15]. The TIV data obtained with at
least four different DSJI devices should help reassure regulatory
bodies including the FDA that administration of TIV by DSJI should
be regarded as equivalent to N–S approaches, with deﬁnitive proof
on this point soon to be available from a large randomized non-
inferiority study by Pharmajet currently underway.
From a tolerability standpoint, there was a signiﬁcant increase
in mild local injection site reactions when TIV was administered
using the Stratis DSJI, in accord with ﬁndings of other DSJI studies
[13–16]. However, local reactions abated within 4 days of immuni-
zation, with the majority lasting less than 2 days. Subjects also re-
ported a higher overall pain score immediately post-immunization
with the Stratis DSJI, in several cases reaching levels of more than 8
out of 10 on a visual analogue scale but reassuringly this pain was
transient and in almost all cases had returned to baseline by
30 min post injection.
Systemic adverse events are more serious than local reactoge-
nicity events from a regulatory standpoint. Interestingly, there
was a signiﬁcant reduction in systemic adverse events, particularly
headaches, reported by subjects who were immunized with the
Stratis DSJI. This reduction in systemic adverse events with the
Stratis DSJI is currently unexplained but could possibly reﬂect dif-
ferences in the rate of systemic release of antigen with the
different injection techniques. Interestingly, a similar but non-sig-
niﬁcant trend towards reduced systemic reactions was also re-
ported in the study of TIV administered by the LectraJet DSJI
device [15]. We speculate that more superﬁcial deposition of the
inﬂuenza vaccine when administering vaccine using DSJI devices
may delay the systemic release of the TIV antigen, and thereby re-
duce the systemic side effects consequent upon a bolus of antigen
entering the systemic circulation.
Subject acceptability of the Stratis DSJI was high with over 50%
expressing a moderate to high interest in having their next inﬂu-
enza vaccine using the DSJI. This was a highly subjective question-
naire administered to gain subjects’ perceptions regarding the useof the Stratis DSJI. The subject population is drawn predominantly
from elderly subjects, most of whom reported having had regular
seasonal N–S inﬂuenza immunizations in the past. Only 25% of
subjects reported anxiety or fear about needles. A different ques-
tionnaire outcome may have been found if the questionnaire was
administered to a group with a higher rate of needle phobia. How-
ever, such subjects were unlikely to volunteer for this study, as
there was a 50% chance they would be randomized to receive the
vaccine by standard injection. In fact, many individuals enquiring
about participation in the study because of publicity of the Stratis
DSJI withdrew their interest when they found that there was no
certainty that they would receive the vaccine through the needle
free device (data not shown). Despite the study population not
being a needle-phobic population, there was nevertheless good
acceptance of the device by the majority of subjects. Immediately
after immunization 90% reported being moderately to extremely
happy with having the inﬂuenza vaccine through the Stratis DSJI
and 80% still felt this way when asked the same question 4 weeks
later. Just two subjects reported not being at all satisﬁed with the
use of the device immediately after they had received the vaccine,
which correlated with their high reported pain scores. However,
one of these subjects relaxed this assessment when asked the same
question 4 weeks later.
Overall, this study highlighted the utility and advantages of the
Stratis DSJI when compared to traditional N–S vaccine delivery.
The device performed well, generated good vaccine immunogenic-
ity, was easy to use with minimal training, and was well accepted
by the majority of subjects. While being associated with an
increased rate of mild injection site reactions this was offset by re-
duced systemic reactions including headaches. In markets where
preﬁlled syringes are not used or not available, the current ﬁeld-
ﬁlled DSJI format where the healthcare worker transfers the vac-
cine from the primary glass container into the needle-free syringe
just prior to delivery, works well. The technology could however
provide further beneﬁt from bringing a pre-ﬁlled syringe option
to the market. Whilst this pilot study was not powered to assess
non-inferiority of inﬂuenza vaccine immunogenicity when admin-
istered by the Stratis DSJI device, an appropriately powered study
44 N. Petrovsky et al. / Trials in Vaccinology 2 (2013) 39–44to address this question is currently underway and when com-
pleted should provide reassurance of the suitability of the Stratis
DSJI device for routine inﬂuenza vaccine delivery.
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